ONCOLOGY Vol 25 No 9

Improved screening practices have lead to a dramatic increase in the diagnosis of ductal carcinoma in situ (DCIS) over the past 40 years.

Few areas in breast disease elicit as much controversy as the management of DCIS. The review by Sanders and Simpson, “Can We Know What to Do When DCIS Is Diagnosed?”

The review of surgical management of neuroendocrine tumors (NETs) of the gastrointestinal tract, authored by Huang, Poultsides, and Norton, is both comprehensive and accessible for readers of all backgrounds.

This article reviews the surgical management of gastrointestinal neuroendocrine tumors, including the preoperative control of hormonal symptoms, extent of resection required, postoperative outcomes, and differing management strategies as determined by whether the tumor has arisen sporadically or as part of a familial disorder, such as multiple endocrine neoplasia type 1.

It is ironic that while huge strides have been made in the treatment of invasive breast carcinoma, resulting in breast conservation for many women, the most appropriate treatment of noninvasive breast carcinoma remains a topic of hot debate.

The patient is a 43-year-old man who was initially evaluated at an outside institution for unexplained anemia and who was found to have a large right kidney mass. He underwent a radical nephrectomy for a 19-cm large-cell, poorly differentiated neoplasm, consistent with pleomorphic, epithelioid angiomyolipoma (EAML) with extensive necrosis and cytologic atypia.

Since 1990, death rates from breast cancer have decreased, mainly in women younger than 50 years of age (3.3% per year) vs women aged 50 years or older (2% per year), reflecting the benefit of widespread use of systemic treatment added to early detection.[1]

Tumors of neuroendocrine origin arising from the pancreas, luminal gastrointestinal tract, and other tissues differ greatly in their malignant potential.

Cancer service leaders must create the vision, embrace the change agenda, and drive the roadmap in order to make the strategic and clinical changeover to value.

This case report presents the management of a very rare tumor. Confronting a rare tumor can be frustrating to both physician and patient.

The authors present an interesting case of a very rare renal neoplasm, malignant epithelioid angiomyolipoma (AML), which belongs to a family of mesenchymal tumors known as perivascular epithelioid tumors (PEComas).

Personalized cancer care is generally thought of as using molecular information from tumors in order to identify which therapeutic agents will be most effective in a given patient.

The Early Breast Cancer Trialists' Collaborative Group overviews published in 2005 confirm that local control in breast cancer matters, and they highlight that achieving local control in the modern era is not improved simply by more extensive surgery but instead by the combination of surgery, systemic and hormonal chemotherapies, and radiation therapy.[1,2]

Mangosteen is an evergreen tree native to Southeast Asian countries, including India, Myanmar, Malaysia, Philippines, Sri Lanka, and Thailand. Its reddish to dark purple fruit, with white juicy edible pulp, is considered one of the best tasting tropical fruits. Mangosteen has a long history of medicinal use to treat skin infections, wounds, and dysentery; in ayurveda, it is used for inflammation, diarrhea, and cholera.

Researchers at the Vanderbilt-Ingram Cancer Center and the Vanderbilt University School of Medicine have parsed the large and heterogeneous triple-negative breast cancer (TNBC) category of patients into 6 molecularly distinct subgroups. This may be an important step towards delineating these patients as specific genetic subtypes to channel them to appropriate targeted therapy trials.

A study in the AACR journal Cancer Prevention Research, has shown evidence that celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, may be a potent chemopreventive agent for lung cancer.